Pirouette is a clinical‑stage pharmaceutical company building OnePush, a partner‑ready, hidden‑needle auto‑injector platform paired with 505(b)(2)/351(k) drug programs across chronic and rescue care. The company is advancing multiple mid-term block-buster potential clinical programs and near‑term out‑licensing assets while scaling U.S. automated manufacturing and IP protection to 2045+.
Pirouette is supported by venture firms and healthcare investors including Safar Partners, Y Combinator, Liquid 2 Ventures, and Gaingels. Recognition includes 2024 Product of the Year from the New Hampshire Tech Alliance for the naloxone auto‑injector and selection for the NIH Innovation Zone at BIO International.
Fully automatic, hidden‑needle, push‑button auto‑injector engineered to reduce needle sensation and lower user burden for chronic at‑home self‑injection and high‑stress rescue use.
Exceeds FDA technical guidance targets for emergency‑use injector reliability, including 99.999% successful injection at 95% confidence and ISO‑aligned environmental qualification.
Market research with 900 patients and 250 HCPs indicates 93% of patients and 88% of prescribers would switch to the OnePush experience for ease‑of‑use and confidence.
Near‑term licensing across naloxone, epinephrine, promethazine, and methotrexate families of auto-injectors.
Pirouette is developing automated manufacturing lines with DSCSA‑ready serialization and surge capacity to meet partner diligence and channel stocking.
Robust IP protection including multiple issued patents across the U.S., Europe, China, and Japan with protection through at least 2045 support long‑term defensibility for partners.
Institutional support led by Safar Partners, Y Combinator, Liquid 2 Ventures, and Gaingels underscores conviction in Pirouette's platform strategy and regulatory path. The community investment exceeded $8M on Wefunder, broadening ownership to stakeholders most impacted by the mission.
"An investment in Pirouette is not just promising; it's a unique opportunity seldom seen in the medical industry, where the public can directly invest in an emerging medical company that will save lives and enable affordable healthcare. Pirouette is poised to revolutionize the $824 Billion injectables market and transform how life-saving injections are administered and accessed."
—Arunas Chesonis
Managing Partner, Safar Partners
"The founders themselves are so well qualified to work on this specific problem. As an investor, you always want to see progress. The thing that kills companies is standing still and this is not a team who under any amount of stress is going to stop working on this product. They not only have the conviction, but they have the operational chops to do so."
—Surbhi Sarna
Biotech Partner, Y Combinator
For investor materials, diligence requests, or partnership discussions, contact the Pirouette team: investors@pirouettepharma.com
All programs are investigational; safety and effectiveness have not been established, and timelines are subject to regulatory review.